Cost-Effectiveness of Photobiomodulation for Intermediate Dry Age-Related Macular Degeneration: A Model-Based Analysis Using the LIGHTSITE III 24-Month Trial.
Arjun Watane, Andre Witkin, Jeffrey Heier et al.
✦ AI-curated · Sources linked
In 30 seconds
This study evaluated the cost-effectiveness of photobiomodulation (PBM) for intermediate dry age-related macular degeneration (AMD) using a model-based analysis from the LIGHTSITE III trial data. The analysis indicated that PBM resulted in 5.244 discounted quality-adjusted life-years (QALYs) at an incremental cost of $29,556 over 10 years, yielding an incremental cost-effectiveness ratio (ICER) of $73,910 per QALY.
Key findings
- PBM produced 5.244 discounted QALYs at an incremental cost of $29,556 over 10 years.
- The base-case ICER was $73,910 per QALY, below the $100,000 and $150,000 thresholds.
- A 71.7% relative reduction in incident geographic atrophy was observed at 24 months.
- The 5-year cumulative national budget impact was estimated at $25.0 billion at 20% uptake.
Why it matters
Understanding the cost-effectiveness of treatments like PBM for intermediate dry AMD is crucial for healthcare decision-making, particularly in resource allocation and insurance coverage considerations. This analysis provides evidence that may influence policy and funding for AMD therapies.